Sophie Steeland
Gent, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial.
Journal: Frontiers in immunology
Published: January 29, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 23, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.
Journal: Expert review of clinical immunology
Published: April 29, 2025
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models.
Journal: Human vaccines & immunotherapeutics
Published: March 03, 2025
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys.
Journal: Journal of immunotoxicology
Published: February 13, 2025
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: November 14, 2023
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Journal: Frontiers in neurology
Published: August 28, 2023
Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.
Journal: Autoimmunity
Published: August 29, 2022
A Study of Cecal Ligation and Puncture-Induced Sepsis in Tissue-Specific Tumor Necrosis Factor Receptor 1-Deficient Mice.
Journal: Frontiers in immunology
Published: August 23, 2019
Choroid plexus tumor necrosis factor receptor 1: A new neuroinflammatory piece of the complex Alzheimer's disease puzzle.
Journal: Neural regeneration research
Published: February 26, 2019
A New Venue of TNF Targeting.
Journal: International journal of molecular sciences
Published: March 31, 2018
Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer's disease.
Journal: EMBO molecular medicine
Published: February 24, 2018
Last Updated: 09/26/2026